---
title: "Weekly Recap | Novavax +5.14%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300190788.md"
description: "Novavax (NVAX) gained 5.14% this week, closing at $10.63. Trading was choppy but tilted upward: the stock opened around $10.38 on Monday, spiked to a weekly high of $11.09 on Tuesday (22 Sep), then settled into a range of $10.33 to $10.79 through Friday. There were no company-specific catalysts during the week, with activity largely driven by healthcare and innovation drug themes across the sector."
datetime: "2026-09-26T06:55:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300190788.md)
  - [en](https://longbridge.com/en/news/300190788.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300190788.md)
generator: "portal-rs"
---

# Weekly Recap | Novavax +5.14%, consensus target above spot

## The Week

Novavax (NVAX) gained 5.14% this week, closing at $10.63. Trading was choppy but tilted upward: the stock opened around $10.38 on Monday, spiked to a weekly high of $11.09 on Tuesday (22 Sep), then settled into a range of $10.33 to $10.79 through Friday. There were no company-specific catalysts during the week, with activity largely driven by healthcare and innovation drug themes across the sector.

## Analyst Ratings

Coverage consists of 9 institutions: 5 rate it buy, 1 hold, 2 underweight and 1 sell. The consensus recommendation is buy, with a consensus target of about $14.00, which sits 31.72% above the latest price of $10.63. Targets range from $7.00 to $25.00, reflecting wide dispersion. Within the biotechnology industry, Novavax ranks 160th out of 506 companies.

## The Week Ahead

The macro calendar is busy next week. On Monday, 28 Sep, the US Dallas Fed manufacturing business activity index is due, with a prior reading of 11.6. Tuesday, 29 Sep, brings the FHFA house price index, Case Shiller 20-city home price index, JOLTS job openings (prior 7.271m) and consumer confidence (prior 89.4). No company earnings are scheduled; the focus remains on sector policy and vaccine-related developments.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [NVAX.US](https://longbridge.com/en/quote/NVAX.US.md)

## Related News & Research

- [Novavax Inc. Stock Outperforms Competitors On Strong Trading Day](https://longbridge.com/en/news/297833178.md)
- [What's Going On With Novavax Stock On Friday?](https://longbridge.com/en/news/285762967.md)
- [Greg Abel-Led Berkshire Hathaway Owns 3 Consumer Stocks. Here's the One I'd Buy First.](https://longbridge.com/en/news/300873098.md)
- [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md)
- [AI's $31.6T Buildout Faces a $6T Revenue Test](https://longbridge.com/en/news/300877631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**